A Pipeline of Precision Therapeutics
A QUANTUM CHANGE
Mirati is developing a pipeline of drug candidates targeting genetic and epigenetic drivers of cancer. Each program is based on a scientific rationale to identify and treat patients most likely to respond to Mirati’s targeted therapies. This includes the use of companion diagnostic assays that detect mutations of specific cancer genes.